Splenic SUMO1 controls systemic inflammation in experimental sepsis

INTRODUCTION: The recent discovery of TAK981(Subasumstat), the first-in-class selective inhibitor of SUMOylation, enables new immune treatments. TAK981 is already in clinical trials to potentiate immunotherapy in metastatic tumors and hematologic malignancies. Cancer patients have more than ten time...

Descripción completa

Detalles Bibliográficos
Autores principales: Youssef, Ayman, Mohammed, Bilal Khan, Prasad, Abhishek, del Aguila, Angela, Bassi, Gabriel, Yang, Wei, Ulloa, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374847/
https://www.ncbi.nlm.nih.gov/pubmed/37520526
http://dx.doi.org/10.3389/fimmu.2023.1200939

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374847/
https://www.ncbi.nlm.nih.gov/pubmed/37520526
http://dx.doi.org/10.3389/fimmu.2023.1200939

Ejemplares similares